(Q51062821)

28 March 2018

title

Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. (English)

1 reference

28 March 2018

main subject

paroxetine

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Goldberg MR

1

1 reference

28 March 2018

Lowry RC

2

1 reference

28 March 2018

Musson DG

3

1 reference

28 March 2018

Birk KL

4

1 reference

28 March 2018

Fisher A

5

1 reference

28 March 2018

De Puy ME

6

1 reference

28 March 2018

Shadle CR

7

1 reference

28 March 2018

publication date

1 February 1999

1 reference

28 March 2018

The Journal of Clinical Pharmacology

published in

1 reference

28 March 2018

volume

39

1 reference

28 March 2018

issue

2

1 reference

28 March 2018

page(s)

192-199

1 reference

28 March 2018

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Quantitation of the 5HT1D agonists MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

The safety of concomitant use of sumatriptan and antidepressant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

The serotonin syndrome. Implicated drugs, pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Pharmacokinetics and food interaction of MK-462 in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

The use of analogue scales in rating subjective feelings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

The use of stable isotope labeling and liquid chromatography/tandem mass spectrometry techniques to study the pharmacokinetics and bioavailability of the antimigraine drug, MK-0462 (rizatriptan) in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

Lack of an Interaction Between Sumatriptan and Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007633

10.1177/00912709922007633

21 January 2018

Identifiers

DOI

1 reference

28 March 2018

1 reference

28 March 2018